Fulgent Genetics Inc. (FLGT)
Summary
Fulgent Genetics, Inc. (FLGT) Q2 2026 Earnings Call Transcript
Fulgent Genetics, Inc. (FLGT) Q2 2026 Earnings Call Transcript
Fulgent Genetics Q2 Earnings Call Highlights
Fulgent Genetics NASDAQ: FLGT reported second-quarter 2026 revenue of $85.4 million, up 20% sequentially and 4% from a year earlier, as the company incorporated a full quarter of contributions from Bako Diagnostics and StrataDx. Management also lowered its full-year revenue outlook, citing lower collection rates during a transition to a new billing and revenue-cycle-management system.
Fulgent Genetics, Inc. (FLGT) Reports Q2 Loss, Misses Revenue Estimates
Fulgent Genetics, Inc. (FLGT) came out with a quarterly loss of $0.58 per share versus the Zacks Consensus Estimate of a loss of $0.46. This compares to earnings of $0.07 per share a year ago.
Fulgent Genetics Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 17 | $338.06 | $315.01 | -$23.05 | -6.82% |
| NA Nizar Araji National Bank Of Canada /FI/ | 1,901 | $103,058.87 | $36,233.06 | -$66,825.81 | -64.84% |
| JM John Malone Amundi | 45,300 | $1.09M | $863,417.95 | -$228,939.93 | -20.96% |
 Point72 Asset Management LP Point72 Asset Management LP | 211,708 | $4.34M | $3.93M | -$414,947.51 | -9.55% |
| YA Yinka Akinsola Blue Trust Inc. | 63 | $1,001.7 | $1,042.65 | $40.95 | 4.09% |
Fulgent Genetics Inc. (FLGT) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Fulgent Genetics Inc. ever had a stock split?
Fulgent Genetics Inc. Profile
| Professional Services Industry | Industrials Sector | Ming Hsieh CEO | NASDAQ (NMS) Exchange | 359664109 CUSIP |
| US Country | 1,315 Employees | - Last Dividend | - Last Split | 29 Sep 2016 IPO Date |
Overview
Fulgent Genetics, Inc., along with its subsidiaries, is a prominent provider of clinical diagnostic and therapeutic development solutions that cater to both physicians and patients across the United States and internationally. Originally established in 2011 under the name Fulgent Diagnostics, Inc., the company underwent a rebranding to Fulgent Genetics, Inc. in August 2016. Operating with its headquarters in El Monte, California, Fulgent Genetics is dedicated to advancing healthcare through its comprehensive range of services and solutions aimed at improving patient outcomes. The company works with various stakeholders in the healthcare sector, including insurance companies, hospitals, medical institutions, other laboratories, governmental bodies, payors, and municipalities, as well as directly with patients.
Products and Services
- Molecular Diagnostic Testing and Genetic Testing: These services include the analysis of DNA, RNA, and proteins to diagnose and monitor disease, predict disease risk, and identify appropriate therapies. They cover a wide range of genetic tests for hereditary cancer, reproductive health, and other diseases.
- Anatomic Pathology Laboratory Tests and Testing Services: This category encompasses a broad spectrum of pathology services, including gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology. These services are essential for the microscopic examination of tissue samples to diagnose various diseases.
- Oncology Tests and Testing Services: Fulgent Genetics offers specialized testing services for the diagnosis and monitoring of cancers. These include the assessment of tumor markers and the genetic profiling of cancers to guide treatment decisions.
- Sequencer Services: The company provides advanced sequencing services to identify mutations and variations in genes associated with hereditary cancers, reproductive health issues, and a range of other diseases. This aids in the personalized management of health conditions.
- Therapeutic Development Solutions: Focusing on the development of drug candidates for treating various cancers, Fulgent Genetics employs a nanoencapsulation and targeted therapy platform. This innovative approach aims to enhance the therapeutic window and pharmacokinetic profiles of new and existing cancer drugs, promising more effective treatments with fewer side effects.
- Picture Genetics Platform: An integrated digital platform offering gene probes, data suppression, and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems. This technology assists customers in identifying critical health markers within their DNA, facilitating personalized medical insights and interventions.
